Of those patients, 221 patients who completed 12 weeks of follow-up with invasive candidiasis were analyzed, including 196 (89%) pediatric patients (Table, Supplemental Digital Content 1 ...

A yeast that could be used to prevent invasive candidiasis – a major cause of death in hospitalized and immunocompromised patients – has been identified by researchers at the Weizmann ...

Background: Invasive candidiasis is an increasing problem in neonatal intensive care units worldwide and is an important cause of morbidity, mortality and prolongation of hospital stay.

Invasive candidiasis is the term for when a yeast infection has spread to other organs of the body. "This induces an inflammatory response and activates your body's immune system to try to clear ...

Bacteria and fungi coexist in microbial communities in nearly all environments, from our bodies to the ocean depths. But when ...

The T2Candida Panel is the only FDA-cleared diagnostic test able to detect sepsis-causing Candida species directly-from-blood, in just 3-5 hours, without the need to wait days for a positive blood ...

Mundipharma and Cidara Therapeutics have received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for rezafungin (rezafungin acetate ...

Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix and BAL2062 -- ...

Reason for decision Not eligible for Health Technology Evaluation guidance Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal ...

We don't wish... In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic ...

Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority ...